Q BioMed Inc.
QBIO
$0.00
$0.000.00%
OTC PK
| 02/28/2023 | 11/30/2022 | 08/31/2022 | 05/31/2022 | 02/28/2022 | |
|---|---|---|---|---|---|
| Revenue | -22.68% | 45.40% | 315.44% | 560.33% | 802.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -22.68% | 45.40% | 315.44% | 560.33% | 802.33% |
| Cost of Revenue | -20.81% | 18.79% | 1.91% | -18.95% | -23.57% |
| Gross Profit | -32.29% | 82.26% | 138.15% | 128.12% | 97.15% |
| SG&A Expenses | -49.17% | -47.13% | -44.53% | -36.69% | -30.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -54.65% | -50.82% | -47.44% | -42.22% | -33.23% |
| Operating Income | 56.04% | 53.36% | 51.02% | 45.90% | 35.83% |
| Income Before Tax | 93.98% | 75.10% | 33.08% | 26.36% | 19.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 93.98% | 75.10% | 33.08% | 26.36% | 19.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 93.98% | 75.10% | 33.08% | 26.36% | 19.66% |
| EBIT | 56.04% | 53.36% | 51.02% | 45.90% | 35.83% |
| EBITDA | 56.50% | 53.73% | 51.30% | 46.13% | 36.01% |
| EPS Basic | 78.76% | 57.89% | 39.11% | 35.59% | 35.90% |
| Normalized Basic EPS | 90.05% | 73.50% | 51.13% | 43.10% | 36.45% |
| EPS Diluted | 78.90% | 58.27% | 38.44% | 34.69% | 35.06% |
| Normalized Diluted EPS | 90.05% | 73.50% | 51.13% | 43.10% | 36.45% |
| Average Basic Shares Outstanding | 130.31% | 67.06% | 33.28% | 22.67% | 20.86% |
| Average Diluted Shares Outstanding | 130.31% | 67.06% | 33.28% | 22.67% | 20.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |